Takeda Pharmaceutical Co ADR [NYSE: TAK] slipped around -0.33 points on Wednesday, while shares priced at $13.29 at the close of the session, down -2.42%.
Compared to the average trading volume of 1.70M shares, TAK reached a trading volume of 3779099 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Takeda Pharmaceutical Co ADR [TAK]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $15.66 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 2.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Takeda Pharmaceutical Co ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 16, 2023. While these analysts kept the previous recommendation, Cowen raised their target price from $21 to $24. The new note on the price target was released on July 19, 2022, representing the official price target for Takeda Pharmaceutical Co ADR stock.
The Average True Range (ATR) for Takeda Pharmaceutical Co ADR is set at 0.19, with the Price to Sales ratio for TAK stock in the period of the last 12 months amounting to 1.39. The Price to Book ratio for the last quarter was 0.87, with the Price to Cash per share for the same quarter was set at 1.89. Price to Free Cash Flow for TAK in the course of the last twelve months was 10.36 with Quick ratio for the last quarter at 0.77.
How has TAK stock performed recently?
Takeda Pharmaceutical Co ADR [TAK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.99. With this latest performance, TAK shares dropped by -5.94% in over the last four-week period, additionally plugging by 1.76% over the last 6 months – not to mention a drop of -5.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 32.45, with the RSI for the last a single of trading hit 28.87, and the three-weeks RSI is set at 35.36 for Takeda Pharmaceutical Co ADR [TAK]. The present Moving Average for the last 50 days of trading for this stock 14.16, while it was recorded at 13.53 for the last single week of trading, and 13.90 for the last 200 days.
Takeda Pharmaceutical Co ADR [TAK]: Deeper insight into the fundamentals
Takeda Pharmaceutical Co ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.77 and a Current Ratio set at 1.28.
Earnings analysis for Takeda Pharmaceutical Co ADR [TAK]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Co ADR go to 33.34%.
Insider trade positions for Takeda Pharmaceutical Co ADR [TAK]
There are presently around $2.45%, or 2.45%% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 13.13 million shares, which is approximately 0.8366%. MONDRIAN INVESTMENT PARTNERS LTD, holding 7.74 million shares of the stock with an approximate value of $$108.34 million in TAK stocks shares; and MONDRIAN INVESTMENT PARTNERS LTD, currently with $$64.53 million in TAK stock with ownership which is approximately 0.3178%.
